TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.

A drug-resistant type of bacteria that has adapted to health care settings evolved in the past several years to weaponize an antimicrobial genetic tool, eliminating its cousins and replacing them as ...

A deadly hospital superbug has evolved into a global force by weaponizing a genetic tool to wipe out its microbial ...

A new study suggests that fluoxetine, commonly known as Prozac, may do more than treat depression. Researchers at the Salk ...

During a health-focused event in New York on Tuesday, Google announced the development of a new collection of “open” AI ...

British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class ...

Pressure mounts on President Claudia Sheinbaum after remains, clothing and apparent crematorium were found at ranch ...

Statistics show hundreds of thousands of systemic bacterial and fungal infections are diagnosed each year in the United ...

- Glyoxalase Domain-containing Protein 4 (GLOD4), the First Identified in a New Class of Enzymes Called Nitrases, Generates ...